BARDA executes option on thermal burn therapy development


The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) executes its option to continue funding the investigation and development of Cytori Therapeutics' (CYTX +0.6%) cell therapy for the treatment of thermal burn injury.

Upon IDE approval by the FDA, BARDA's funding will be ~$8.3M which will pay for the remaining R&D that will enable a pilot clinical trial. It will also fund ~two years of preclinical studies in other burn-related areas.

The contract retains two additional options to fund a pivotal clinical trial ($45M) and work in thermal burn complicated by radiation exposure ($23M).

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs